trending Market Intelligence /marketintelligence/en/news-insights/trending/AWIOzU-ivxmgjNapC-T0hg2 content esgSubNav
In This List

US FDA grants uniQure breakthrough therapy designation for hemophilia drug

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


US FDA grants uniQure breakthrough therapy designation for hemophilia drug

The U.S. FDA granted uniQure NV breakthrough therapy designation for AMT-060, an investigational gene therapy for patients with severe hemophilia B.

Hemophilia B is a serious and rare inherited disease in males characterized by insufficient blood clotting.

The designation is based on the ongoing phase 1 and 2 studies of the drug that show sustained increases in Factor IX, reductions in Factor IX replacement usage and a near cessation of spontaneous bleeding in patients with severe disease at up to 12 months follow-up.